Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01055444 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome
A Phase 2 study of Shoulder Impingement Syndrome, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01055444 is a Phase 2 study of Shoulder Impingement Syndrome that has completed, run by ZARS Pharma. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01055444, a Phase 2 study of Shoulder Impingement Syndrome, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to explore the potential usefulness of a heated lidocaine 70 mg/tetracaine 70 mg topical patch for the treatment of pain associated with shoulder impingement syndrome
Conditions Studied
Interventions
- DRUG Heated lidocaine and tetracaine topical patch
Study Locations (1)
Idaho
- Injury Care Medical Center - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01055444
The ClinicalTrials.gov registry entry for NCT01055444 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Shoulder Impingement Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Heated lidocaine and tetracaine topical patch is the first listed.
NCT01055444 reports 1 study location spanning 1 distinct geographic area - top geographies include Idaho.
Frequently Asked Questions
What is clinical trial NCT01055444 about?
NCT01055444 is a clinical study titled "Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome". The purpose of the study is to explore the potential usefulness of a heated lidocaine 70 mg/tetracaine 70 mg topical patch for the treatment of pain associated with shoulder impingement syndrome
What is the current status of trial NCT01055444?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-03. Estimated completion is 2010-09.
What conditions does trial NCT01055444 study?
This clinical trial studies the following conditions: Shoulder Impingement Syndrome.
What interventions are being tested in trial NCT01055444?
The interventions under investigation include: Heated lidocaine and tetracaine topical patch (DRUG).
Who is sponsoring clinical trial NCT01055444?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01055444 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shoulder Impingement Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.